Open AccessChemoradiotherapy for patients with locally advanced or unresectable extra-hepatic biliary cancer
Author(s) -
Krishan R. Jethwa,
Shilpa Sannapaneni,
Trey C. Mullikin,
William S. Harmsen,
M. Petersen,
Phanindra Antharam,
Brady Laughlin,
Amit Mahipal,
Þorvarður R. Hálfdánarson,
Kenneth W. Merrell,
M.A. Neben-Wittich,
Terence T. Sio,
Michael G. Haddock,
Christopher L. Hallemeier
Publication year - 2020
Publication title -
journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.084
H-Index - 39
eISSN - 2219-679X
pISSN - 2078-6891
DOI - 10.21037/jgo-20-245
Subject(s) - medicine , gallbladder cancer , proportional hazards model , cumulative incidence , chemoradiotherapy , confidence interval , hazard ratio , univariate analysis , adverse effect , retrospective cohort study , gallbladder , cohort , surgery , cancer , gastroenterology , multivariate analysis
Although surgical resection is the preferred curative-intent treatment option for patients with non-metastatic, extra-hepatic biliary cancer (EBC), radiotherapy (RT) or chemoradiotherapy (CRT) may be utilized in select cases when surgical resection is not feasible. The purpose of this study is to report the efficacy and adverse events (AEs) associated with CRT for patients with locally advanced and unresectable EBC.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom